Parabilis Medicines Inc(PBLS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 23 at 4:00 PM ET (Korea 10/24 05:00)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | - | Insider Own | 37.28% | Shs Outstand | 121.9M | Perf Week | 7.43% |
| Market Cap | 3.02B | Forward P/E | - | EPS next Y | - | Insider Trans | 91.17% | Shs Float | 77.5M | Perf Month | -24.73% |
| Enterprise Value | 1.95B | PEG | - | EPS next Q | -0.36 | Inst Own | 50.95% | Short Float | 10.66% | Perf Quarter | -23.19% |
| Income | - | P/S | - | EPS this Y | - | Inst Trans | 120.65% | Short Ratio | 10.36 | Perf Half Y | - |
| Sales | - | P/B | 2.88 | EPS next 5Y | - | ROA | - | Short Interest | 8.26M | Perf YTD | -26.72% |
| Book/sh | 8.48 | P/C | 2.69 | EPS past 3/5Y | - | ROE | - | 52W High | -42.47% ($42.49) | Perf Year | - |
| Cash/sh | 9.07 | P/FCF | - | Sales past 3/5Y | - | ROIC | - | 52W Low | 7.86% ($22.66) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | - | Gross Margin | - | Volatility(W/M) | 10.87% 9.36% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 2.63 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 17.91 | EPS Q/Q | - | Profit Margin | - | RSI (14) | 36.02 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 17.91 | Sales Q/Q | - | SMA20 | -12.95% ($28.08) | Beta | - | Target Price | $41.4 |
| Payout | - | Debt/Eq | 0.05 | Earnings | 2026/8/13 | SMA50 | -28.36% ($34.12) | Rel Volume | 2.28 | Prev Close | $26.92 |
| Employees | - | LT Debt/Eq | 0.03 | EPS/Sales Surpr. | -1306.06% -99.3% | SMA200 | -24.74% ($32.47) | Avg Volume(3M) | 0.80M | Price | $24.44 |
| IPO | 2026/6/10 | Option/Short | Yes/Yes | Trades | 13130 | Volume | 1,820,814 | Change | -9.21% |
🧬 This is a clinical-stage oncology biopharmaceutical company that uses its proprietary Helicon platform technology to target protein targets that have historically been difficult to drug. The company focuses on developing innovative new medicines by designing stabilized alpha-helical peptides to modulate intracellular protein-protein interactions.
Over the past 1 year, on the lower side
42% below its 1-year high.
Traded more than usual. That is 228% of its average volume.
Not enough quarters to judge yet
Only 1 quarter(s) reported, so no grade yet.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Long-term returns are roughly flat
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 51.0%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #71 of 595 in the industry
Based on market cap of $3B.
TLX#68 Telix Pharmaceuticals Ltd ADR $3B PER 97.9 
VKTX#69 Viking Therapeutics Inc $3B PER - 
ELVN#70 Enliven Therapeutics Inc $3B PER - PBLS#71 Parabilis Medicines Inc $3B PER - 
DNLI#72 Denali Therapeutics Inc $3B PER - 
FAQ
What kind of company is PBLS?
PBLS belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of PBLS?
The market cap of PBLS is approximately $3.0B, ranking 1,744 within its sector.
What is the 52-week high and low for PBLS?
PBLS has recorded a 52-week high of $42.49 and a low of $22.66.
